Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence.

Gruchalla RS, Sampson HA, Matsui E, David G, Gergen PJ, Calatroni A, Brown M, Liu AH, Bloomberg GR, Chmiel JF, Kumar R, Lamm C, Smartt E, Sorkness CA, Steinbach SF, Stone KD, Szefler SJ, Busse WW.

J Allergy Clin Immunol. 2009 Aug;124(2):213-21, 221.e1. doi: 10.1016/j.jaci.2009.05.036. Epub 2009 Jul 16.

3.

Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.

Lenney W, McKay AJ, Tudur Smith C, Williamson PR, James M, Price D; MASCOT Study Group.

Health Technol Assess. 2013 Feb;17(4):1-218. doi: 10.3310/hta17040.

4.

Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.

Gelb AF, Taylor CF, Simmons M, Shinar C.

Pulm Pharmacol Ther. 2009 Dec;22(6):516-21. doi: 10.1016/j.pupt.2009.05.003. Epub 2009 May 23.

PMID:
19467341
5.

Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.

Rabinovitch N, Mauger DT, Reisdorph N, Covar R, Malka J, Lemanske RF Jr, Morgan WJ, Guilbert TW, Zeiger RS, Bacharier LB, Szefler SJ.

J Allergy Clin Immunol. 2014 Feb;133(2):350-6. doi: 10.1016/j.jaci.2013.07.039. Epub 2013 Sep 29.

6.

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.

Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bloomberg GR, Covar RA, Guilbert TW, Heldt G, Larsen G, Mellon MH, Morgan WJ, Moss MH, Spahn JD, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2007 Jan;119(1):64-72. Epub 2006 Nov 30. Erratum in: J Allergy Clin Immunol. 2007 Aug;120(2):285.

PMID:
17140647
7.

Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: residual volume and exhaled nitric oxide as outcome measures.

Verini M, Peroni DG, Piacentini GL, Nicodemo A, Rossi N, Bodini A, Chiarelli F, Boner AL.

Allergy Asthma Proc. 2007 Nov-Dec;28(6):691-4. doi: 10.2500/aap.2007.28.3054.

PMID:
18201433
8.

Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.

Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.

Clin Ther. 2008 Aug;30(8):1492-504. doi: 10.1016/j.clinthera.2008.07.018.

PMID:
18803991
9.

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.

Calhoun WJ, Nelson HS, Nathan RA, Pepsin PJ, Kalberg C, Emmett A, Rickard KA, Dorinsky P.

Am J Respir Crit Care Med. 2001 Sep 1;164(5):759-63.

PMID:
11549529
10.
11.

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.

Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P.

Pharmacoeconomics. 2002;20(13):909-18.

PMID:
12381242
12.

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.

Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM.

J Allergy Clin Immunol. 2005 Feb;115(2):233-42.

PMID:
15696076
13.

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.

Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ.

Chest. 2001 Apr;119(4):1021-6.

PMID:
11296164
14.

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ.

Am J Respir Crit Care Med. 2003 May 1;167(9):1232-8. Epub 2002 Nov 27.

PMID:
12456382
15.

Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy.

Dorinsky PM, Edwards LD, Yancey SW, Rickard KA.

Clin Ther. 2001 May;23(5):701-14.

PMID:
11394729
16.

Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity.

Horner CC, Mauger D, Strunk RC, Graber NJ, Lemanske RF Jr, Sorkness CA, Szefler SJ, Zeiger RS, Taussig LM, Bacharier LB; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2011 Nov;128(5):977-82.e1-2. doi: 10.1016/j.jaci.2011.07.018. Epub 2011 Sep 8.

17.

Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.

Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer A.

Respir Med. 2007 Dec;101(12):2437-46. Epub 2007 Oct 1. Erratum in: Respir Med. 2008 Jun;102(6):937-8.

18.

Allergen-specific IgE as a biomarker of exposure plus sensitization in inner-city adolescents with asthma.

Matsui EC, Sampson HA, Bahnson HT, Gruchalla RS, Pongracic JA, Teach SJ, Gergen PJ, Bloomberg GR, Chmiel JF, Liu AH, Kattan M, Sorkness CA, Steinbach SF, Story RE, Visness CM; Inner-city Asthma Consortium.

Allergy. 2010 Nov;65(11):1414-22. doi: 10.1111/j.1398-9995.2010.02412.x.

20.

Seasonal risk factors for asthma exacerbations among inner-city children.

Teach SJ, Gergen PJ, Szefler SJ, Mitchell HE, Calatroni A, Wildfire J, Bloomberg GR, Kercsmar CM, Liu AH, Makhija MM, Matsui E, Morgan W, O'Connor G, Busse WW.

J Allergy Clin Immunol. 2015 Jun;135(6):1465-73.e5. doi: 10.1016/j.jaci.2014.12.1942. Epub 2015 Mar 18.

Supplemental Content

Support Center